The use of a commercial ELISA for assay of thrombin-antithrombin complexes in purified systems.
Inhibition of thrombin by antithrombin III (AT) results in the formation of stable thrombin-AT complexes (TAT). An enzyme-linked immunosorbent assay (ELISA) following the sandwich principle is available for the determination of TAT complexes in human plasma, however, this ELISA method could not be used in purified systems containing thrombin and AT. It has therefore been modified for use in purified systems and an excellent correlation was found between the disappearance of thrombin and AT and the recovery of TAT complexes. Addition of thrombin inhibitor hirudin and heparin inhibitor polybrene into the reacting thrombin-AT mixture did not interfere with the assay of TAT. It was found that the use of siliconised tubes was necessary for the conservation of the TAT complexes.
Department of Clinical Chemistry and Blood Coagulation, Karolinska Institute, Stockholm, Sweden.
G
G
Elgue
B
B
Pasche
M
M
Blombäck
P
P
Olsson
D000990:Antithrombin III / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D010447:Peptide Hydrolases / Q000032:analysis*; D015203:Reproducibility of Results; D013048:Specimen Handling; D013917:Thrombin / Q000032:analysis*
C046193:antithrombin III-protease complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D013917:Thrombin